title: Sequential role of hippocampus and amygdala, entorhinal cortex and parietal cortex in formation and retrieval of memory for inhibitory avoidance in rats.
abstract: The hippocampus and amygdala, the entorhinal cortex and the parietal cortex participate, in that sequence, both in the formation and in the expression of memory for a step-down inhibitory avoidance task in rats. Bilateral infusion of AP5 or muscimol caused retrograde amnesia when given 0 min after training into both hippocampus and amygdala, when given or 180 min after training into the entorhinal cortex, or when given 180 min after training into the parietal cortex. Therefore, memory formation requires the sequential and integrated activity of all these areas mediated by glutamate NMDA receptors in each case. Pre-test administration of CNQX 1 day after training into hippocampus and amygdala, 1 or 31 days after training in entorhinal cortex, or 1, 31 or 60 days after training in the parietal cortex temporarily blocked retention test performance. Therefore, 1 day after training, all these brain structures are necessary for retrieval; 1 month later, the hippocampus and amygdala are no longer necessary for retrieval but the entorhinal and parietal cortex still are; and 60 days after training only the parietal cortex is needed. In all cases the mechanisms of retrieval require intact glutamate AMPA receptors.
authors.affiliation: Centro de Memoria, Departamento de Bioquimica, Instituto de Biociencias, Universidade Federal do Rio Grande do Sul (UFRGS) (centro),Porto Alegre, Brazil.
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo
authors.forename: J A
authors.initials: JA
authors.lastname: Quillfeldt
authors.forename: M S
authors.initials: MS
authors.lastname: Zanatta
authors.forename: J
authors.initials: J
authors.lastname: Quevedo
authors.forename: E
authors.initials: E
authors.lastname: Schaeffer
authors.forename: P K
authors.initials: PK
authors.lastname: Schmitz
authors.forename: J H
authors.initials: JH
authors.lastname: Medina
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000494:pharmacology; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000008:administration & dosage / Q000494:pharmacology; D000648:Amnesia, Retrograde / Q000139:chemically induced / Q000503:physiopathology; D000679:Amygdala / Q000502:physiology*; D000818:Animals; D001362:Avoidance Learning / Q000502:physiology*; D001931:Brain Mapping; D018728:Entorhinal Cortex / Q000502:physiology*; D005106:Exploratory Behavior; D007839:Functional Laterality; D006624:Hippocampus / Q000502:physiology*; D007263:Infusions, Parenteral; D008297:Male; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D009118:Muscimol / Q000008:administration & dosage / Q000494:pharmacology; D010296:Parietal Lobe / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D009118:Muscimol; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D015763:2-Amino-5-phosphonovalerate